Cargando…
Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Final analysis of a 52‐week phase 3 open‐label study
In this 52‐week, phase 3 open‐label study, efficacy and safety of adalimumab were evaluated in Japanese patients with active ulcers due to pyoderma gangrenosum (PG) during a 26‐week treatment period and another 26‐week extension period. Patients received adalimumab 160 mg at week 0, 80 mg at week 2,...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313851/ https://www.ncbi.nlm.nih.gov/pubmed/35243682 http://dx.doi.org/10.1111/1346-8138.16337 |